ATP 2016

DOSE CONSTRAINTS

 Maximum tolerated doses and optimum fractionation for mediastinal structures is currently unknown  Toxicity for SBRT delivered to central tumors is not well documented  Serious doubts in the validity of available data, mostly coming from retrospective series with small sample sizes  Lacking, incomplete or inconsistent reporting on dose specification  Questionable use of EqD2, α/ß-ratios, LQM estimates

Summary of current experiences in dose/ fraction - toxicity coherences after SBRT to the mediastinal structures that lead to LungTech normal tissue constraints

German Cancer Consortium (DKTK)